![\"\"](\"https:\/\/www.tigerandtech.com\/wp-content\/uploads\/2026\/01\/1-8-1024x682.jpg\")
<\/figure>\n\n\n\n\"Patent industrialization + stock options\"<\/p>\n\n\n\n
What's the new model?<\/p>\n\n\n\n
Behind the province's first single<\/p>\n\n\n\n
And what are the stories of innovation?<\/p>\n\n\n\n
\ud83d\udc47<\/strong>0<\/strong>1<\/strong><\/p>\n\n\n\n Nanjing Ningji Biomedical Technology Co.The industrialized body of Prof. Yong Chu's team at Fudan University, dedicated to solving the clinical challenges of primary immune thrombocytopenia<\/strong>The<\/p>\n\n\n\n Primary immune thrombocytopenia, which is an autoimmune disease, due to autoimmune factors, resulting in a decrease in the number of platelets in the body, common symptoms are purpura, nosebleeds and even gastrointestinal bleeding, intracranial hemorrhage and so on. For a long time, patients rely on hormones or hemostatic drugs for treatment, which has a lot of side effects and is easy to recur after stopping the drugs.<\/p>\n\n\n\n Is there an innovative drug that can go from \"treating the symptoms\" to \"treating the root cause\"? In the long-term scientific research, Chu Yong and his team have made a new discovery.GSK-3\u03b2 was first identified as a key target for the treatment of the disease<\/strong>--Both regulates macrophages to reduce platelet destruction; and influences megakaryocytes to promote platelet production, striking at the heart of the pathology.<\/p>\n\n\n\n Disease treatment has a new direction, the surprise, but also the problem: how to industrialize the laboratory's innovations? Where does the money come from?<\/p>\n\n\n\n \"Early R & D will face many risks, if the funds are limited, we can only bet on the possibility of one of the multiple candidate molecules.\" Chu Yong frankly admitted that in this \"initial kilometer\" of the results of the transformation, do not promote, the results can only stay in the paper; but if you promote, from the preclinical candidate molecules to the clinical application of new drugs to declare the stage of the project will face a funding gap.<\/p>\n\n\n\n 02<\/strong><\/p>\n\n\n\n \"Dilemma\" at the time, a cooperation invitation from the north of the river, open a new situation.<\/p>\n\n\n\n The sub-center came into contact with Chu Yong's team during a project roadshow event at Fudan University. \"Innovative target mechanism, remarkable immunomodulation efficacy, and deep involvement of clinical experts are exactly the type of support most needed for early transformation.\" Xu Tong recalled that after professional and technical evaluation, the sub-center decided to support the team's achievement transformation.<\/p>\n\n\n\n At that time, the Intellectual Property Office of Jiangsu Province and the Local Finance Bureau of Jiangsu Province jointly issued the \"Jiangsu Province Patent Industrialization + Ownership\" Work Plan, exploring the \"Patent Industrialization + Ownership\" mode. The branch center also sent a special \"transformation gift\".<\/p>\n\n\n\n \"There are three parts to the 'gift'.\" Xu Tong explains.The first part is the real money support, the sub-center with early project transformation start-up funds, injected into the team millions of dollars of special support<\/strong>The second part is service support. The second part is service support. The technical consultant of the sub-center helps Chuyong team to jointly formulate the project R&D plan, including setting milestone nodes, docking with CRO enterprises, etc., and each link is followed up by a person to ensure that it meets the specification requirements for new drug R&D.<\/p>\n\n\n\n Part Three.<\/strong>And the most innovative part<\/strong>--The sub-centers convert their early investment in the project into \"stock options\" in the enterprise.<\/strong>This means that the sub-center currently contributes money and efforts to support the transformation of achievements, and does not require immediate access to equity or repayment of dividends, but in exchange for a future right. When the enterprise develops and grows, and its value is increasedSub-centers can get the corresponding equity at the now agreed price<\/strong>The<\/p>\n\n\n\n \"There is both financial and service support, and you don't have to give up a lot of equity at the early stage when the valuation is at its lowest.\" Chu Yong said that such support allowed the team to devote themselves to transformation without distractions.<\/p>\n\n\n\n In the view of the staff of the sub-centers, this model brings a \"win-win\" situation.\"Everyone shares the risk of transformation.\"<\/strong>Xu Tong said, when the research team and the transformation platform to become \"the same way\", not only to promote the industrialization of cutting-edge biomedical technology, but also the formation of a sustainable value return mechanism, to achieve \"technology - capital - industry to realize the efficient linkage of \"technology-capital-industry\".<\/p>\n\n\n\n 03<\/strong><\/p>\n\n\n\n Now, the sub-center held by the condensation of biological options, has been in the Jiangsu equity trading center options integrated service platform to complete the registration of trusteeship, for the future exercise of rights to provide protection.<\/p>\n\n\n\n Coordinates Fudan University School of Pharmacy, Prof. Chu Yong and his team alsoSmall molecule drug candidates have been successfully completed<\/strong>PCC phase validation of YC-4-3<\/strong>The industrialization process is accelerating, which will hopefully lead to safer and more effective oral innovative drugs for patients.<\/p>\n\n\n\n The province's first single \"patent industrialization + stock options\" fusion mode in Jiangbei successfully landed.Behind the scenes is a vivid story of \"accompanying the conversion\"<\/strong>As a bridge between the science and technology chain and the industrial chain, the sub-center has explored more than that. As a bridge connecting the science and technology chain and the industrial chain, in order to better promote the transformation of scientific and technological achievements of universities into real productivity, the sub-center explores more than that--<\/p>\n\n\n\n The province's first university scientific and technological achievements transformation angel fund, with a total scale of 500 million yuan, has invested in several projects for the transformation of results to lower the threshold, improve efficiency; with the Bank of Jiangsu special customized \"results transformation loan\", through the innovative \"signing of the loan\" approach, the support of up to 30 million yuan; jointly with the Bank of Nanjing launched the \"R & D pipeline loan\" to help the project to convert intellectual property into real assets. The \"R&D Pipeline Loan\", jointly launched with Bank of Nanjing, helps the project transform intellectual property rights into actual assets. ...... A series of innovative initiatives are escorting the whole chain of university results transformation, and promoting more results in the laboratory to the production line.<\/p>\n\n\n\n \"In the future, the sub-center will continue to stimulate the innovation vitality of researchers and attract more social capital to pay attention to and invest in early-stage scientific and technological innovation with the 'patent industrialization + stock option' model.\" Xu Tong said.<\/p>\n\n\n\n <\/p>","protected":false},"excerpt":{"rendered":" Recently, the national university biomedical regional technology transfer center (Nanjing, Jiangsu Province) (referred to as \"sub-center\") held by the Nanjing Ningshi Biomedical Technology Co.<\/p>","protected":false},"author":2,"featured_media":15735,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[84,56],"tags":[],"class_list":["post-15734","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-chan_ye_lian_xun_xi","category-zi_jin_zhi_chi"],"acf":[],"yoast_head":"\n![\"\"](\"https:\/\/www.tigerandtech.com\/wp-content\/uploads\/2026\/01\/2-2.png\")
<\/figure>\n\n\n\n![\"\"](\"https:\/\/www.tigerandtech.com\/wp-content\/uploads\/2026\/01\/3-4-1024x683.jpg\")
<\/figure>\n\n\n\n![\"\"](\"https:\/\/www.tigerandtech.com\/wp-content\/uploads\/2026\/01\/4-4-1024x766.jpg\")
<\/figure>\n\n\n\n